Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,809 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,163 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00100841 | Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer | completed | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00510250 | A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer | completed | Phase 1 / Phase 2 | 13 | University Health Network, TorontoOTHER | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00072267 | UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | — | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT01561482 | Study of Metformin With Simvastatin for Men With Prostate Carcinoma | withdrawn | Phase 2 | 0 | Nicholas MitsiadesOTHER | 1 | Jul 22, 2015 | clinicaltrials |
| NCT00936975 | Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2015 | clinicaltrials |
| NCT01436214 | Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer | unknown | Phase 1 / Phase 2 | 60 | Adamis Pharmaceuticals CorporationINDUSTRY | 1 | Jul 16, 2015 | clinicaltrials |
| NCT01808534 | Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors | terminated | Phase 2 | 5 | Indiana UniversityOTHER | 1 | Jul 2, 2015 | clinicaltrials |
| NCT00739830 | Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6) | completed | Phase 2 | 130 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 1, 2015 | clinicaltrials |
| NCT00108732 | A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2015 | clinicaltrials |
| NCT02049190 | Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 75 | Arno TherapeuticsINDUSTRY | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00058539 | Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer | completed | Phase 2 | 42 | Genentech, Inc.INDUSTRY | 0 | Jun 23, 2015 | clinicaltrials |
| NCT01175772 | Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy | terminated | Phase 2 | 6 | HaEmek Medical Center, IsraelOTHER | 1 | Jun 23, 2015 | clinicaltrials |
| NCT00365443 | Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003) | withdrawn | Phase 2 | 0 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 19, 2015 | clinicaltrials |
| NCT01705652 | Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients(Nexrutine) | terminated | Phase 2 | 21 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT01880996 | Tai-chi / Qi-gong in Patients With Patients With Gynecological Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Sheba Medical CenterOTHER_GOV | 1 | Jun 11, 2015 | clinicaltrials |
| NCT00096993 | A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 131 | Genentech, Inc.INDUSTRY | 1 | Jun 10, 2015 | clinicaltrials |
| NCT01690598 | Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status | completed | Phase 1 / Phase 2 | 22 | Vejle HospitalOTHER | 1 | Jun 10, 2015 | clinicaltrials |
| NCT00260039 | Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001) | completed | Phase 2 | 680 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 8, 2015 | clinicaltrials |
| NCT00551187 | A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) | completed | Phase 2 | 620 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 8, 2015 | clinicaltrials |
| NCT02424513 | A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer | withdrawn | Phase 2 | 0 | ImaginAb, Inc.INDUSTRY | 1 | Jun 2, 2015 | clinicaltrials |
| NCT00217633 | Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer | completed | Phase 2 | 38 | Gynecologic Oncology GroupNETWORK | 2 | May 29, 2015 | clinicaltrials |
| NCT00118066 | Calcitriol in Preventing Prostate Cancer in Patients With Prostatic Intraepithelial Neoplasia | terminated | Phase 2 | 12 | Rutgers, The State University of New JerseyOTHER | 1 | May 27, 2015 | clinicaltrials |
| NCT01200797 | SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin | terminated | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | May 25, 2015 | clinicaltrials |
| NCT01379534 | A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer | completed | Phase 2 | 53 | Novartis PharmaceuticalsINDUSTRY | 7 | May 20, 2015 | clinicaltrials |
| NCT02188550 | Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer | unknown | Phase 2 | 20 | Sinai Hospital of BaltimoreOTHER | 1 | May 19, 2015 | clinicaltrials |
| NCT00343044 | Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers | completed | Phase 2 | 40 | Benaroya Research InstituteOTHER | 1 | May 15, 2015 | clinicaltrials |
| NCT00072566 | Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | May 12, 2015 | clinicaltrials |
| NCT00430781 | Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer | completed | Phase 2 | 228 | GlaxoSmithKlineINDUSTRY | 13 | May 8, 2015 | clinicaltrials |
| NCT00743379 | Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 71 | Threshold PharmaceuticalsINDUSTRY | 1 | May 7, 2015 | clinicaltrials |
| NCT02235324 | Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT02435186 | p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | unknown | Phase 2 | 100 | Shenzhen SiBiono GeneTech Co.,LtdINDUSTRY | 1 | May 6, 2015 | clinicaltrials |
| NCT00303823 | Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia | completed | Phase 2 | 98 | National Cancer Institute (NCI)NIH | 1 | May 5, 2015 | clinicaltrials |
| NCT01196741 | Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer(SaPPrOC) | completed | Phase 2 / Phase 3 | 107 | University College, LondonOTHER | 1 | May 5, 2015 | clinicaltrials |
| NCT00715104 | Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer(NeoACT) | completed | Phase 2 | 42 | DendreonINDUSTRY | 1 | May 4, 2015 | clinicaltrials |
| NCT00039585 | Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00267696 | Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | Phase 2 | 45 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00020254 | Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00500110 | Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer | completed | Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 28, 2015 | clinicaltrials |
| NCT00975429 | Study Using WST11 in Patients With Localized Prostate Cancer | completed | Phase 2 | 86 | Steba Biotech S.A.OTHER | 3 | Apr 28, 2015 | clinicaltrials |
| NCT02425163 | Shear Wave Elastography of Prostate Cancer(ElaProC) | completed | Phase 2 | 73 | University of MagdeburgOTHER | 1 | Apr 23, 2015 | clinicaltrials |
| NCT00673127 | Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer(KHAD) | completed | Phase 2 | 57 | Beth Israel Deaconess Medical CenterOTHER | 2 | Apr 22, 2015 | clinicaltrials |
| NCT00176293 | Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer | terminated | Phase 2 | 2 | University of KentuckyOTHER | 1 | Apr 21, 2015 | clinicaltrials |
| NCT02420587 | AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 20, 2015 | clinicaltrials |
| NCT00003880 | Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer | terminated | Phase 2 / Phase 3 | 132 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 16, 2015 | clinicaltrials |
| NCT00217464 | Fulvestrant in Treating Patients With Recurrent Prostate Cancer | terminated | Phase 2 | 17 | Roswell Park Cancer InstituteOTHER | 1 | Apr 16, 2015 | clinicaltrials |
| NCT02406365 | Diagnostic Imaging Aid for Management of Cervical Lesions(FFC) | unknown | Phase 2 | 618 | Brookdale University Hospital Medical CenterOTHER | 1 | Apr 10, 2015 | clinicaltrials |
| NCT02095847 | High-Resolution Microendoscopy to Guide Hysteroscopic Tumor Resection | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 8, 2015 | clinicaltrials |
| NCT00215683 | An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer | completed | Phase 2 / Phase 3 | 137 | Ferring PharmaceuticalsINDUSTRY | 7 | Apr 1, 2015 | clinicaltrials |
| NCT01267266 | Saracatinib in Treating Patients With Prostate Cancer | terminated | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Apr 1, 2015 | clinicaltrials |
| NCT00260611 | Study of Oxaliplatin and Taxotere in Prostate Cancer | completed | Phase 2 | 34 | University of PittsburghOTHER | 1 | Mar 25, 2015 | clinicaltrials |
Data updated 24 days agoSource updated Jul 27, 2015source: clinicaltrials